MARKET WIRESeeking Alpha • 7h ago
Aktis Oncology: Padcev Is Building The Market It WantsSeeking Alpha report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
Why AKTS Stock dropped -5.46% Today — RQD Quant Desk Flash
$15.93 -5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $15.74
Aktis Oncology Inc. (AKTS) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $937.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AKTS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $15.93 (-5.46% 1D, market cap $937.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AKTS ranks #499 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AKTS compare to KURA and ORIC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KURA (Kura Oncology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AKTS?
▼
Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $15.74 (-1.17%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AKTS)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY AKTS SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0.7% FCF Margin ($26.2M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$17.34-12.9% Next Q
49
Q2 (-2Q)Grade D$15.11+4.1% Next Q
46
Q3 (-1Q)Grade D$15.73+1.3% Next Q
44
CurrentGrade D-$15.93-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AKTS Turnaround Squeeze
While AKTS currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.43) and Max Pain ($16.73) forces dealer call-delta covering toward $35.90.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AKTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AKTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AKTS Stock dropped -5.46% Today — RQD Quant Desk Flash
Aktis Oncology Inc. (AKTS) dropped -5.46% to $15.93, trading at 6% of its 52-week range ($14.72 – $34.19). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($14.72 – $34.19) with RSI-14 at 44.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.5% around $15.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $26.2M annual free cash flow.
Live AKTS Headlines & Catalysts
CATALYSTMarketBeat • 10h ago
93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LPMarketBeat report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 13h ago
Aktis Oncology, Inc. Common stock (NASDAQ: AKTS) Share Price, AKTS Stock News, AKTS Share Price & Updateskalkine.ca report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 16h ago
Aktia (HLSE:AKTIA) Stock Looks Above Fair Value After A 70% RunYahoo Finance report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 19h ago
Akso Health Group (AHG) Stock May Look Pricey Against Its Book ValueYahoo Finance report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 22h ago
Aktis Oncology Q3 2026 Earnings Date and EstimatesMarketBeat report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Obsidian Therapeutics (Nasdaq:OBX) - Stock AnalysisSimply Wall St report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Vivani Medical, Inc. (VANI) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AKTS)
- ✓Walkthrough of AKTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AKTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.16%▼ DESCENDING CHANNEL
2026-11-02O $16.82H $16.85L $15.93C $15.93VOL 245.7K
RES: $21.84SUP: $13.66SMA50: $20.43SMA200: $21.00
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AKTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AKTS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AKTS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AKTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AKTS)
Health Care Rank #499 of 1016
⚔️ KURA vs AKTS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AKTS vs. KURA, ORIC, CYRX, ANRO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aktis Oncology Inc. (AKTS) ranks #499 by composite RQD confidence (41/100, grade D-) and #369 by equity capitalization ($937.2M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. CYRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with AKTS at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AKTS
ACTIVE
Aktis Oncology Inc. | D- | 41/100 | — | — | — | -5.46% | $937.2M | Benchmark Subject |
| KURA Kura Oncology Inc. | E | 32/100 | — | — | -35.0% | -2.84% | $939.4M | /kura-vs-akts → |
| ORIC Oric Pharmaceuticals Inc. | E | 29/100 | — | — | -33.4% | +2.78% | $931.8M | /oric-vs-akts → |
| CYRX CryoPort Inc. | D- | 43/100 | 11.8x | 47.1% | -11.5% | -5.47% | $926.4M | /cyrx-vs-akts → |
| ANRO Alto Neuroscience Inc. | D- | 35/100 | — | — | -35.0% | -3.71% | $921.0M | /anro-vs-akts → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002035832In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aktis Oncology Inc. (AKTS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, AKTS closed FY2025 with $264.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $264.9M | — |
3. AKTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AKTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Aktis Oncology Inc. (NASDAQ: AKTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $15.93 (-5.46% 1D, market cap $937.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AKTS ranks #499 in composite RQD confidence.
How does AKTS compare to KURA and ORIC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTS carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KURA (Kura Oncology Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $939.4M) and ORIC (Oric Pharmaceuticals Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AKTS?
Per AKTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002035832), Aktis Oncology Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $264.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AKTS trading relative to its 50-day, 200-day, and 52-week technical levels?
AKTS last traded at $15.93 (-5.46% on volume of 251,549 shares), positioning the stock -22.03% below its 50-day simple moving average ($20.43) and -24.14% below its 200-day simple moving average ($21.00). Across its 52-week range of $14.72 to $34.19, AKTS sits at the 6.2% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.5% ($14.10 to $17.76).
AKTS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AKTS stock moving today?
Why AKTS Stock dropped -5.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 41/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AKTS — Aktis Oncology Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:27Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AKTS scores 41 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
- Fundamental Cash Engine: 10 / 20. The rating reflects an ROIC of 0% and an FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free cash generation to support valuation on cash-flow grounds.
- Whale 13F Flow: 3 / 20. This is the weakest pillar, covering institutional accumulation and options positioning. Source data does not contain holder detail (see Analyst View section), so the low score signals limited observable institutional support in the rating's inputs.
- Insider Conviction: 9 / 20. The score reflects SEC Form 4 and Congressional PTR cluster flow. Specific transactions are not itemized in the source data.
- Macro Regime Fit: 6 / 20. The rating cites a Beta of 1.0 and sector sensitivity. A market-matching beta means the stock is not structurally insulated from broad market moves.
- Forensic Balance Sheet: 13 / 20. This is the strongest pillar, citing an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. These figures suggest a moderately sound balance sheet relative to the rating's other inputs.
Investor implication: the upside case rests mainly on balance-sheet durability and news-driven catalysts rather than on current earnings or cash generation. The valuation tradeoff is that the source data provides no earnings-based multiples to anchor price, so the market price of $16.85 cannot be tested against profitability in this dataset. This brief is educational and not personalized financial advice.
Business
Aktis Oncology Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the profile section. The source data does not describe its products, customers, or revenue model. Revenue for FY 2025 is reported as $0.0M per the SEC financials, which is consistent with a company not yet generating reported product revenue in that period. The source data does not identify how the company intends to monetize its work.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | $37.8M | N/A |
Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $37.8M. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5 within its forensic balance sheet pillar. Debt is listed as N/A in the SEC financials, so the Debt/Equity figure is not reconcilable to a reported debt amount in the source data.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the following items reference AKTS:
- "Aktis Oncology: Padcev Is Building The Market It Wants" (Seeking Alpha, 1h ago, YELLOW, MARKET WIRE). Risk watch: the headline references Padcev, but the source data does not describe the relationship or its financial effect.
- "93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP" (MarketBeat, 3h ago, GREEN, CATALYST). A reported share acquisition by a single institution; the source data does not state the position size relative to outstanding shares.
- "Aktis Oncology, Inc. Common stock ... Share Price, AKTS Stock News" (kalkine.ca, 6h ago, YELLOW, MARKET WIRE). General market-update item with no specific event described.
- "Aktia (HLSE:AKTIA) Stock Looks Above Fair Value After A 70% Run" (Yahoo Finance, 9h ago, YELLOW, MARKET WIRE). This headline concerns a different issuer (Aktia, HLSE listing) and is not verifiably about AKTS; treat it as an unrelated item.
- "Akso Health Group (AHG) Stock May Look Pricey Against Its Book Value" (Yahoo Finance, 12h ago, GREEN, CATALYST). This headline concerns a different issuer (Akso Health Group) and is not verifiably about AKTS; treat it as an unrelated item.
- "Aktis Oncology Q3 2026 Earnings Date and Estimates" (MarketBeat, 15h ago, YELLOW, MARKET WIRE). The source data does not provide the earnings date or estimate figures.
Butterfly Supply-Chain Graph: Sector Health Care, industry Biotechnology: Pharmaceutical Preparations, supply chain listed as NONE, with no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations for AKTS. A prospective investor should note that 2nd-order ripple analysis cannot be performed from this dataset. The one externally named relationship, Padcev, appears only in a headline and is not mapped in the graph. Watch items: whether any collaboration referenced in news materially changes revenue, and whether the company's zero reported revenue persists into later filings.
Open Questions
- What products or programs does Aktis Oncology develop, and what is the status of any clinical or commercial milestones?
- What is the nature of the Padcev relationship referenced in the news, and does it carry financial terms?
- What is the reported debt balance, given that Debt is listed as N/A while Debt/Equity is cited as 0.5?
- What is the FY 2026 financial trajectory and the Q3 2026 earnings results, since the source data contains only FY 2025 figures?
- Which institutional holders and insiders are involved in the reported flow, given that the holders section is empty?
AKTS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Aktis Oncology Inc. (AKTS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 7h ago
Aktis Oncology: Padcev Is Building The Market It Wants Seeking Alpha report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 10h ago
93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP MarketBeat report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 13h ago
Aktis Oncology, Inc. Common stock (NASDAQ: AKTS) Share Price, AKTS Stock News, AKTS Share Price & Updates kalkine.ca report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 16h ago
Aktia (HLSE:AKTIA) Stock Looks Above Fair Value After A 70% Run Yahoo Finance report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 19h ago
Akso Health Group (AHG) Stock May Look Pricey Against Its Book Value Yahoo Finance report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 22h ago
Aktis Oncology Q3 2026 Earnings Date and Estimates MarketBeat report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Obsidian Therapeutics (Nasdaq:OBX) - Stock Analysis Simply Wall St report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Vivani Medical, Inc. (VANI) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Aktis Oncology Inc. (AKTS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AKTS Bull vs. Bear Conversation Board — What's Your Call at $15.93?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AKTS 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $14.83 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AKTS (D- • RQD 41/100) a Buy at $16.85?
Welcome to the AKTS (Aktis Oncology Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $13.31 (-21.0%)
Spot @ $16.85 Pump the brakes on AKTS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AKTS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aktis Oncology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $20.89 (+24.0%)
Spot @ $16.85 AKTS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AKTS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $16.85 (52-wk range $14.72 - $34.19), any beat on forward guidance forces shorts and underweight funds to chase.